MedTrace Logo

Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity

NCT00199745 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2012-05-10

No results posted yet for this study

Summary

The primary objective of the study is to investigate whether differences in atorvastatin metabolite ratios might have a positive or negative predictive value in diagnosing atorvastatin muscle toxicity. A muscle biopsy is also collected and investigated.

Conditions

  • Muscular Diseases

Interventions

DRUG

atorvastatin

Sponsors & Collaborators

  • University of Oslo School of Pharmacy

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Kjetil Retterstøl, MD · Lipidklinikken, Rikshospitalet-Radiumhospitalet HF

  • Anders Åsberg, Associate Professor · Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199745 on ClinicalTrials.gov